Download 11-2-2016 PPT

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
PHARMACOKINETICS
VOLUMES AND PROTEIN
BINDING
VOLUMES AND PROTEIN BINDING
 Which of the following alteration in protein binding is likely to
be the most clinically significant acutely?




A. Volume of distribution=2, fut is increased
B. Volume of distribution=150, fut is decreased
C. Volume of distribution=2, fut is decreased
D. Volume of distribution=150, fup is increased
VOLUMES AND PROTEIN BINDING
 If fup is increased, which of the following situations would
most likely require a change in MD?




A. Low E drug IV
B. Low E drug PO
C. High E drug IV
D. High E drug PO
VOLUMES AND PROTEIN BINDING
 When do you see a “spike” on the time vs concentration graph
(aka transient increase) when fup is increased?





A. Both PO and IV Low E drugs
B. High E drug given IV
C. Only Low E drug given IV
D. High E drug given PO
E. Both A and D
VOLUMES AND PROTEIN BINDING
 When are you likely to see a clinically significant effect if fup is
changed?




Low or High protein binding?
Wide or narrow therapeutic index?
High or Low E drug?
IV or PO?
VOLUMES AND PROTEIN BINDING
 Which of the following would result in the most clinically
significant (concerning) situation?




A. Nonlinear elimination
B. Nonlinear plasma protein binding
C. Both
D. Neither
VOLUMES AND PROTEIN BINDING
 Describe the phases of nonlinear protein binding:
DOSE DEPENDENCE
DOSE DEPENDENCE
 CL,T=300 ml/min, fe=0.1. If this drug exhibits non -linear
pharmacokinetics, what will be af fected causing an increase
in AUC?




A. Because
B. Because
C. Because
D. Because
it is a high extraction drug, the CL will be affected
it is a low extraction drug, the CL will be affected
it is a high extraction drug, the F will be affected
it is a low extraction drug, the F will be affected.
DOSE DEPENDENCE
High Extraction Drugs
 CL=
 F*=
 Non-linear PK
manifests in:
 Terminal slope will be:
 Half life:
Low Extraction Drugs
 CL=
 F*=
 Non-linear PK
manifests in:
 Terminal slope will be:
 Half-life:
DOSE DEPENDENCE
DOSE DEPENDENCE
DOSE DEPENDENCE
QUESTIONS?
Related documents